Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer.

Autor:	Roviello G; Division of Medical Oncology, Department of Onco-Hematology, IRCCS-CROB, Referral Cancer Center of Basilicata, 85028 Rionero, Vulture (PZ), Italy., Corona SP; Peter MacCallum Cancer Centre, Radiation Oncology Department, Moorabbin Campus, East Bentleigh, Victoria 3165, Australia., Multari AG; Unit of Medical Oncology, Department of Oncology, Ospedale San Donato, 52100, Arezzo, Italy., Paganini G; Unit of general medicine, Azienda Ospedaliera 'C. Poma' Presidio ospedaliero di Pieve di Coriano, ASST Mantova, Italy., Chiriacò G; Medical Oncology Unit, Department of Oncology, ASST del Garda, 25015 Desenzano del Garda (BS), Italy., Conca R; Division of Medical Oncology, Department of Onco-Hematology, IRCCS-CROB, Referral Cancer Center of Basilicata, 85028 Rionero, Vulture (PZ), Italy., Petrioli R; Department of Medicine, Surgery and Neurosciences, Medical Oncology Unit, University of Siena, Viale Bracci - Policlinico 'Le Scotte', 53100, Siena, Italy., Generali D; Department of Medical, Surgery and Health Sciences, University of Trieste, 34129 Trieste, Italy.; Breast Cancer and Translational Research Unit, ASST Cremona, 26100 Cremona, Italy., Rosellini P; Department of Medicine, Surgery and Neurosciences, Medical Oncology Unit, University of Siena, Viale Bracci - Policlinico 'Le Scotte', 53100, Siena, Italy., Aieta M; Division of Medical Oncology, Department of Onco-Hematology, IRCCS-CROB, Referral Cancer Center of Basilicata, 85028 Rionero, Vulture (PZ), Italy.
Jazyk:	angličtina
Zdroj:	Oncotarget [Oncotarget] 2018 Apr 27; Vol. 9 (32), pp. 22332-22339. Date of Electronic Publication: 2018 Apr 27 (Print Publication: 2018).
DOI:	10.18632/oncotarget.24900
Abstrakt:	Purpose: Hypertension (HTN) is frequently associated with the use of angiogenesis inhibitors targeting the vascular endothelial growth factor pathway, such as ramucirumab. The aim of this study was to retrospectively evaluate if occurrence of HTN is correlated with response to second line treatment with ramucirumab+paclitaxel for metastatic gastric cancer. Methods: Treatment consisted of ramucirumab 8 mg/kg intravenously (iv) on days 1 and 15, plus paclitaxel 80 mg/m 2 iv on days 1, 8, and 15 of a 28-day cycle. Patients received study treatment until disease progression, unacceptable toxicity, or withdrawal of consent. Results: Thirty-four patients were retrospectively evaluated. Among these, 6 (17.6%) developed grade 3 ramucirumab-induced HTN. These patients had a better outcome than those with lesser grades events, with a progression-free survival (PFS) of 7.8 months (95% CI 4.4-not reached) versus 4.2 months (95% CI 3.1-5.2) (p=0.001). overall survival (OS) was 11.9 months (95% CI 9.3-not reached) in the grade 3 HTN group, versus 7.2 months (95% CI 5.9-10.1). Conclusions: Despite the small number of patients and the retrospective nature of the data, our analysis showed that occurrence of ramucirumab-related HTN, in particular G3 HTN, predicts response to treatment with ramucirumab+paclitaxel in patients with metastatic gastric cancer. Competing Interests: CONFLICTS OF INTEREST All authors declare no actual or potential conflicts of interest, including any financial, personal or other relationships with people or organizations (within three years from the beginning of the submitted work) that could influence, or be perceived to influence, this work.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu